{"id":"NCT03268954","sponsor":"Takeda","briefTitle":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","officialTitle":"A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-28","primaryCompletion":"2021-05-28","completion":"2024-10-14","firstPosted":"2017-08-31","resultsPosted":"2022-09-22","lastUpdate":"2024-10-28"},"enrollment":454,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelodysplastic Syndrome","Leukemia, Myelomonocytic, Chronic","Leukemia, Myeloid, Acute"],"interventions":[{"type":"DRUG","name":"Azacitidine","otherNames":[]},{"type":"DRUG","name":"Pevonedistat","otherNames":[]}],"arms":[{"label":"Azacitidine 75 mg/m^2","type":"EXPERIMENTAL"},{"label":"Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants with low-blast AML).","primaryOutcome":{"measure":"Event-Free Survival (EFS)","timeFrame":"From randomization until transformation to acute myeloid leukemia, or death due to any cause up to data cut-off date: 28 May 2021 (up to approximately 42 months)","effectByArm":[{"arm":"Azacitidine 75 mg/m^2","deltaMin":15.7,"sd":null},{"arm":"Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2","deltaMin":17.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.557"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":242,"countries":["United States","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Israel","Italy","Japan","Mexico","Poland","Russia","South Korea","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35728048"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b60294db2bf003ab499ea"]},"adverseEventsSummary":{"seriousAny":{"events":142,"n":220},"commonTop":["Constipation","Anaemia","Neutropenia","Thrombocytopenia","Nausea"]}}